A Phase 1b (OX1222) Dose-Finding Study of OXi4503 Combined with Cytarabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

被引：0
|
作者：
Watts, Justin M. [1 ]
Swords, Ronan T. [2 ]
Cogle, Christopher R. [3 ]
Lin, Tara L. [4 ]
机构：
[1] Univ Miami, Leukemia Program, Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Florida, Div Hematol Oncol, Dept Med, Gainesville, FL USA
[4] Univ Kansas Canc Ctr, Kansas City, KS USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.4037.4037
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4037
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
    van Eijkelenburg, Natasha K. A.
    Rasche, Mareike
    Ghazaly, Essam
    Dworzak, Michael N.
    Klingebiel, Thomas
    Rossig, Claudia
    Leverger, Guy
    Stary, Jan
    De Bont, Eveline S. J. M.
    Chitu, Dana A.
    Bertrand, Yves
    Brethon, Benoit
    Strahm, Brigitte
    van der Sluis, Inge M.
    Kaspers, Gertjan J. L.
    Reinhardt, Dirk
    Zwaan, C. Michel
    [J]. HAEMATOLOGICA, 2018, 103 (09) : 1484 - 1492
  • [42] Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)
    Kadia, Tapan M.
    Benton, Christopher
    Erba, Harry P.
    Gandhi, Mitul
    Levy, Moshe Y.
    Percival, Mary-Elizabeth M.
    Ulrickson, Matthew
    Yimer, Habte
    Yu, Min
    Chen, Zi
    Wang, Jing
    Li, Mingyu
    Ahmad, Mohammad
    Yang, Dajun
    Zhai, Yifan
    [J]. BLOOD, 2022, 140 : 11659 - 11660
  • [43] A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia
    Saxena, Kapil
    Herbrich, Shelley M.
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Borthakur, Gautam
    Pierce, Sherry A.
    Jabbour, Elias
    Wang, Sa A.
    Bueso-Ramos, Carlos
    Loghavi, Sanam
    Tang, Guillin
    Cheung, Cora M.
    Alexander, Lynette
    Kornblau, Steven
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Konopleva, Marina Y.
    Daver, Naval
    [J]. CANCER, 2021, 127 (20) : 3761 - 3771
  • [44] Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
    Sekiguchi, Naohiro
    Kasahara, Senji
    Miyamoto, Toshihiro
    Kiguchi, Toru
    Ohno, Hitoshi
    Takagi, Taiga
    Tachibana, Masaya
    Sumi, Hiroyuki
    Kakurai, Yasuyuki
    Yamashita, Tomonari
    Usuki, Kensuke
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (01) : 68 - 77
  • [45] Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia
    Naohiro Sekiguchi
    Senji Kasahara
    Toshihiro Miyamoto
    Toru Kiguchi
    Hitoshi Ohno
    Taiga Takagi
    Masaya Tachibana
    Hiroyuki Sumi
    Yasuyuki Kakurai
    Tomonari Yamashita
    Kensuke Usuki
    [J]. International Journal of Hematology, 2023, 117 : 68 - 77
  • [46] A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.
    Heidel, Florian
    Ribrag, Vincent
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Passamonti, Francesco
    Hayat, Amjad
    Conneally, Eibhlin
    Kindler, Thomas
    Martino, Bruno
    Lipka, Daniel B.
    Acharyya, Suddhasatta
    Binlich, Florence
    Liu, Tracy
    Mu, Song
    Harrison, Claire N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia
    Vey, Norbert
    Prebet, Thomas
    Thalamas, Claire
    Charbonnier, Aude
    Rey, Jerome
    Kloos, Ioana
    Liu, Emily
    Luan, Ying
    Vezan, Remus
    Graef, Thorsten
    Recher, Christian
    [J]. LEUKEMIA & LYMPHOMA, 2017, 58 (08) : 1880 - 1886
  • [48] Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study
    Pardee, Timothy S.
    Luther, Sanjeev
    Buyse, Marc
    Powell, Bayard L.
    Cortes, Jorge
    [J]. FUTURE ONCOLOGY, 2019, 15 (28) : 3197 - 3208
  • [49] Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    Pemmaraju, Naveen
    Borate, Uma
    Solh, Melhem
    Borthakur, Gautam M.
    DeZern, Amy E.
    Zhang, Chao
    Powell, Ben
    Severson, Paul
    Inokuchi, Kerry
    Matusow, Bernice
    Halladay, Jason
    Hsu, Ching
    Watkins, Paul
    Walling, Jackie M.
    Tsiatis, Athanasios C.
    Mims, Alice S.
    [J]. BLOOD, 2019, 134
  • [50] Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
    Ravandi, Farhad
    Bashey, Asad
    Foran, James
    Stock, Wendy
    Mawad, Raya
    Short, Nicholas
    Yilmaz, Musa
    Kantarjian, Hagop
    Odenike, Olatoyosi
    Patel, Anand
    Garcha, Raman
    Ainsworth, William Barrett
    Clynes, Raphael
    Kanodia, Jitendra
    Ding, Ying
    Li, Huajiang
    Kye, Steve
    Mims, Alice
    [J]. BLOOD ADVANCES, 2023, 7 (21) : 6492 - 6505
12345